You are here:

lisdexamfetamine dimesylate (Elvanse)

Advice

following a full submission:

lisdexamfetamine dimesylate (Elvanse®) is accepted for use within NHS Scotland.

Indication under review: as part of a comprehensive treatment programme for attention deficit/hyperactivity disorder (ADHD) in children aged 6 years of age and over when response to previous methylphenidate treatment is considered clinically inadequate.

In a multi-centre, randomised, double-blind, controlled study in children and adolescents with ADHD, treatment with lisdexamfetamine was associated with a shorter time to first response compared with a non-stimulant, centrally-acting sympathomimetic agent.  A greater proportion of lisdexamfetamine treated patients achieved improvements in symptom scores and functioning than those treated with the active comparator.

Drug Details

Drug Name: lisdexamfetamine dimesylate (Elvanse)
SMC Drug ID: 863/13
Manufacturer: Shire Pharmaceuticals
Indication: As part of a comprehensive treatment programme for attention deficit/hyperactivity disorder (ADHD) in children aged 6 years of age and over when response to previous methylphenidate treatment is considered clinically inadequate.
BNF Category:
Submission Type: Full submission
Status: Accepted
Date Advice Published: 13 May 2013

Back